Bioequivalence of two kinds of domestic simvastatin capsules in healthy volunteers
Dan Liu
Abstract
Dan Liu
Abstract
Objective To study the bioequivalence of two kinds of domestic simvastatin capsules in healthy volunteers.Methods A single oral dose of 40 mg simvastatin was given to 20 healthy volunteers in an open randomized crossover design;The concentrations of simvastatin in plasma were determined by HPLC-MS/MS method.The pharmacokinetic parameters were calculated by DAS 2.1 software.Results The main pharmacokinetic parameters of two preparations were as follows:tmax were(1.7±0.6) and(1.8±0.7) h;Cmax were(12.23±4.62) and(12.73±4.31) ng·mL-1;t1/2 were(4.2±1.6) and(4.1 ±1.4) h;AUC0-t were(42.27±27.61) and(41.81±27.75) ng·h·mL-1;AUC0-∞ were(43.99±28.60) and(43.32±28.47)ng·h·mL-1.The relative bioavailability of simvastatin was(101.8±15.8)%.Conclusion The results of demonstrated that the two preparations of simvastatin were bioequivalent.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Objective To study the bioequivalence of two kinds of domestic simvastatin capsules in healthy volunteers.Methods A single oral dose of 40 mg simvastatin was given to 20 healthy volunteers in an open randomized crossover design;The concentrations of simvastatin in plasma were determined by HPLC-MS/MS method.The pharmacokinetic parameters were calculated by DAS 2.1 software.Results The main pharmacokinetic parameters of two preparations were as follows:tmax were(1.7±0.6) and(1.8±0.7) h;Cmax were(12.23±4.62) and(12.73±4.31) ng·mL-1;t1/2 were(4.2±1.6) and(4.1 ±1.4) h;AUC0-t were(42.27±27.61) and(41.81±27.75) ng·h·mL-1;AUC0-∞ were(43.99±28.60) and(43.32±28.47)ng·h·mL-1.The relative bioavailability of simvastatin was(101.8±15.8)%.Conclusion The results of demonstrated that the two preparations of simvastatin were bioequivalent.
Key concepts: Simvastatin, Bioequivalence, Cmax, Pharmacokinetics, Bioavailability, Crossover study, Pharmacology, Medicine